drugset / Trial / NCT00681525

A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe

NCT00681525

Phase 1 Completed 18 enrolled Abbott
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study is to evaluate the potential PK interaction between ABT-335, atorvastatin 80 mg and ezetimibe 10 mg when administered concurrently.

Timeline

Start
2008-04
Primary completion
2008-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-335 Small molecule 135 mg
Subject Atorvastatin Small molecule 80 mg
Subject Ezetimibe Unknown 10 mg

Indications

No indication recorded.